Physician profile
Shenon E Badre
NPI 1407929276
$9,299.70
in general payments reported to CMS, 2019-2025
48 companies · $1,653 in 2025
The $1,653 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,536 · 2020: $1,202 · 2021: $1,223 · 2022: $1,164 · 2023: $1,153 · 2024: $1,368 · 2025: $1,653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,174.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $1,541.34 | 2019-2025 | Omnipod |
| Novo Nordisk INC | $1,166.18 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $805.07 | 2019-2025 | Jardiance, Mounjaro, Baqsimi |
| Abbott Laboratories | $603.94 | 2019-2025 | Freestyle Libre, Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $454.59 | 2019-2025 | Tepezza, Evenity, Repatha |
| Astrazeneca Pharmaceuticals LP | $415.63 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $387.80 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $368.44 | 2019-2025 | Jardiance |
| Dexcom, INC. | $341.66 | 2019-2025 | Dexcom G6 Transmitter |
| Mannkind Corporation | $297.17 | 2019-2024 | Afrezza |
| Radius Health, INC. | $250.57 | 2019-2025 | |
| Medtronic, INC. | $250.37 | 2021-2025 | Minimed 780g |
| Janssen Pharmaceuticals, INC | $232.73 | 2019 | |
| Abbvie INC. | $168.68 | 2019-2025 | |
| Ibsa Pharma INC. | $166.44 | 2019-2025 | Licart, Tirosint, Tirosint |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $155.31 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $155.02 | 2019-2021 | |
| Corcept Therapeutics | $154.37 | 2023-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $121.41 | 2020-2025 | Gvoke Hypopen |
| Medtronic Minimed, INC. | $108.04 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $96.36 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Endo Pharmaceuticals INC. | $93.85 | 2020-2021 | |
| Averitas Pharma INC. | $90.13 | 2024-2025 | Qutenza |
| Beta Bionics, INC. | $71.49 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Sequel Med Tech, LLC | $66.55 | 2025 | Twiist |
| Ascendis Pharma Endocrinology INC | $57.01 | 2023-2025 | Yorvipath |
| Valeritas, INC. | $53.65 | 2019 | |
| Kyowa Kirin, INC. | $52.69 | 2023-2024 | Crysvita |
| Ultragenyx Pharmaceutical INC. | $51.07 | 2021-2023 | |
| Shire North American Group INC | $49.58 | 2019 | |
| Esperion Therapeutics, INC. | $48.80 | 2021-2025 | Nexletol |
| Madrigal Pharmaceuticals | $44.57 | 2025 | Rezdiffra |
| Horizon Therapeutics Plc | $43.26 | 2020-2022 | |
| Cequr Corporation | $38.84 | 2024 | Cequr Simplicity |
| Rgh Enterprises LLC | $31.35 | 2025 | |
| Senseonics, Incorporated | $28.00 | 2020 | |
| Globus Medical, INC. | $24.73 | 2025 | Senza |
| Novartis Pharmaceuticals Corporation | $24.16 | 2023 | |
| Zealand Pharma US, INC. | $23.12 | 2021 | |
| Soleno Therapeutics, INC. | $23.02 | 2025 | Vykat Xr |
| Almatica Pharma LLC | $20.61 | 2024 | Teriparatide |
| Vistapharm, INC. | $19.00 | 2021 | |
| Ascensia Diabetes Care US INC. | $18.76 | 2023 | |
| Amneal Pharmaceuticals LLC | $18.22 | 2024 | Unithroid |
| Pfizer INC. | $17.31 | 2019 | |
| Amarin Pharma, INC. | $16.76 | 2020 | |
| Neurocrine Biosciences, INC. | $16.05 | 2025 | |
| Astellas Pharma US INC | $16.00 | 2023 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shenon Badre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.